Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, Climent MA. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study. Clinical Genitourinary Cancer. 2022; 20(1)DOI:10.1016/j.clgc.2021.09.006. PMID:34789409. IF:3.200(Q2/4D).

Duarte, V, Zaror, C, Villanueva, J, Andreo, M, Dallaserra, M, Salazar, J, Pont, A, Ferrer, M. Oral Health-Related Quality of Life Changes in Patients with Dentofacial Deformities Class II and III after Orthognathic Surgery: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health. 2022; 19(4)DOI:10.3390/ijerph19041940. PMID:35206128. IF:4.614(Q1/3D).

Cortellini, A, Ricciuti, B, Vaz, VR, Soldato, D, Alessi, JV, Dall'Olio, FG, Banna, GL, Muthuramalingam, S, Chan, S, Majem, M, Piedra, A, Lamberti, G, Andrini, E, Addeo, A, Friedlaender, A, Facchinetti, F, Gorria, T, Mezquita, L, Hoton, D, Valerie, L, Nana, FA, Artingstall, J, Comins, C, Di Maio, M, Caglio, A, Cave, J, McKenzie, H, Newsom-Davis, T, Evans, JS, Tiseo, M, D'Alessio, A, Fulgenzi, CAM, Besse, B, Awad, MM, Pinato, DJ. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. Journal for ImmunoTherapy of Cancer. 2022; 10(2)DOI:10.1136/jitc-2021-004374. PMID:35173031. IF:10.900(Q1/2D).

Kuemmel, S, Campone, M, Loirat, D, Lopez, RL, Beck, JT, De Laurentiis, M, Im, SA, Kim, SB, Kwong, A, Steger, GG, Adelantado, EZ, Duhoux, FP, Greil, R, Kuter, I, Lu, YS, Tibau, A, Ozguroglu, M, Scholz, CW, Singer, CF, Vega, E, Wimberger, P, Zamagni, C, Couillebault, XM, Fan, LQ, Guerreiro, N, Mataraza, J, Sand-Dejmek, J, Chan, A. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH. 2022; 28(1)DOI:10.1158/1078-0432.CCR-20-3955. PMID:34615719. IF:11.500(Q1/1D).

Osuna-Gomez, R, Arqueros, C, Galano, C, Mulet, M, Zamora, C, Barnadas, A, Vidal, S. Effector Mechanisms of CD8+HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy. Cancers. 2021; 13(24)DOI:10.3390/cancers13246167. PMID:34944786. IF:6.575(Q1/3D).

Rubio-Viqueira, B, Tarruella, MM, Lazaro, M, Estevez, SV, Cordoba-Ortega, JF, Maiques, IM, Gonzalez, JG, Cordellat, AB, Valdivia-Bautista, J, Arenas, CG, Torres, JMS. PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study. Lung Cancer Management. 2021; 10(4)DOI:10.2217/lmt-2021-0008. PMID:34899993. IF:(Q/D).

Caamano, AG, Vicente, AMGM, Maroto, P, Antolin, AR, Sanz, J, Gonzalez, MAV, Climent, MA. Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group. Current Oncology. 2021; 28(6)DOI:10.3390/curroncol28060428. PMID:34940067. IF:3.109(Q3/8D).

Iglesias, P, Peiro, I, Biagetti, B, Paja-Fano, M, Cobo, DA, Gomez, CG, Mateu-Salat, M, Genua, I, Majem, M, Riudavets, M, Gavira, J, Lamas, C, Pombo, AF, Guerrero-Perez, F, Villabona, C, Agricola, JMC, Webb, SM, Diez, JJ. Immunotherapy-induced isolated ACTH deficiency in cancer therapy. ENDOCRINE-RELATED CANCER. 2021; 28(12)DOI:10.1530/ERC-21-0228. PMID:34609950. IF:5.905(Q1/3D).

Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11)DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4.090(Q2/4D).

Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021) (vol 24, pg 646, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02855-2. PMID:35596046. IF:3.400(Q3/6D).

Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021) (vol 24, pg 712, 2022). Clinical & Translational Oncology. 2022; 24(7)DOI:10.1007/s12094-022-02846-3. PMID:35567734. IF:3.400(Q3/6D).

Majem, M, de las Penas, R, Virizuela, JA, Cabezon-Gutierrez, L, Cruz, P, Lopez-Castro, R, Mendez, M, Mondejar, R, Munoz, MD, Escobar, Y. SEOM clinical guideline emesis (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02802-1. PMID:35347571. IF:3.400(Q3/6D).

Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Álava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., López Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2021; 32(12)DOI:10.1016/j.annonc.2021.08.1995. PMID:34500044. IF:51.769(Q1/1D).

Valcarcel, S, Gallego, J, Jimenez-Fonseca, P, Diez, M, de Castro, EM, Hernandez, R, Arrazubi, V, Custodio, A, Cano, JM, Montes, AF, Macias, I, Visa, L, Calvo, A, Tocino, RV, Lago, NM, Limon, ML, Granja, M, Gil, M, Pimentel, P, Macia-Rivas, L, Perez, CH, Mangas, M, Carnicero, AM, Cerda, P, Gonzalez, LG, Navalon, FG, Rambla, MDM, Richard, MM, Carmona-Bayonas, A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; 149(7)DOI:10.1007/s00432-022-04294-6. PMID:36042046. IF:2.700(Q3/6D).

Isla D., Felip E., Garrido P., Insa A., Majem M., Remon J., Trigo J.M., de Castro J.. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical & Translational Oncology. 2023; 25(1)DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:2.800(Q2/5D).

Aparicio, J, Manrique, ACV, Capdevila, J, Boza, FM, Galvan, P, Richart, P, Oliveres, H, Paez, D, Hernando, J, Serrano, S, Vera, R, Hernandez-Yague, X, Gallego, RA, Riesco-Martinez, MC, de Albeniz, XG, Maurel, J. Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Clinical & Translational Oncology. 2022; 24(11)DOI:10.1007/s12094-022-02868-x. PMID:35761123. IF:3.400(Q3/6D).

Climent, MA, Font, A, Duran, I, Puente, J, Mendez-Vidal, MJ, Saez, MI, Lobera, CS, Arija, JAA, Gonzalez-Del-Alba, A, Sanchez-Hernandez, A, Fita, MJJ, Esteban, E, Alonso-Gordoa, T, Gonzalez, BM, Maroto, P, Lazaro-Quintela, M, Cassinello-Espinosa, J, Perez-Valderrama, B, Garcias, C, Castellano, D. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. EUROPEAN JOURNAL OF CANCER. 2022; 175DOI:10.1016/j.ejca.2022.08.002. PMID:36099670. IF:8.400(Q1/2D).

Herbst, RS, Majem, M, Barlesi, F, Carcereny, E, Chu, Q, Monnet, I, Sanchez-Hernandez, A, Dakhil, S, Camidge, DR, Winzer, L, Soo-Hoo, Y, Cooper, ZA, Kumar, R, Bothos, J, Aggarwal, C, Martinez-Marti, A. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(29)DOI:10.1200/JCO.22.00227. PMID:35452273. IF:45.300(Q1/1D).

Gonzalez-Barrallo, I, Rubio, VEC, Medina, J, Espana, S, Mujika, K, Majem, M, Aguado, C, Suarez, MAC, Palacio, I, Osterloh, L, Martinez-Fernandez, A, Garcia-Castano, A. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). MELANOMA RESEARCH. 2022; 32(5)DOI:10.1097/CMR.0000000000000837. PMID:35762583. IF:2.200(Q3/7D).

Alserawan, L, Anguera, G, Atenza, CZ, Lopez, JS, Martinez-Martinez, L, Melia, MR, Sullivan, I, Joaquin, AB, Tarruella, MM, Vidal, S. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(20)DOI:10.3390/ijms232012641. PMID:36293498. IF:5.600(Q1/3D).

Majem, M, Alvarez, R, Ortega, AL, de Alda, LR, Gordo, R, Garcia, JF, Ivanova-Markova, Y, Gonzalez-Dominguez, A, San Cristobal, RS, Rojo, F. Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Global & Regional Health Technology Assessment. 2022; 9DOI:10.33393/grhta.2022.2449. PMID:36628311. IF:(Q/D).

Hwang, TJ, Kesselheim, AS, Tibau, A, Lee, CC, Vokinger, KN. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice. 2022; 18(9)DOI:10.1200/OP.21.00909. PMID:35731996. IF:4.000(Q2/4D).

Casarrubios, M, Provencio, M, Nadal, E, Insa, A, Garcia-Campelo, MD, Lazaro-Quintela, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Bernabe, R, Vinolas, N, Aranda, IB, Massuti, B, Sierra-Rodero, B, Martinez-Toledo, C, Fernandez-Miranda, I, Serna-Blanco, R, Romero, A, Calvo, V, Cruz-Bermudez, A. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Journal for ImmunoTherapy of Cancer. 2022; 10(9)DOI:10.1136/jitc-2022-005320. PMID:36171009. IF:10.900(Q1/2D).

Hernandez, A, Munoz-Marmol, AM, Esteve-Codina, A, Alameda, F, Carrato, C, Pineda, E, Arpi-Llucia, O, Martinez-Garcia, M, Mallo, M, Gut, M, del Barco, S, Gallego, O, Dabad, M, Mesia, C, Bellosillo, B, Domenech, M, Vidal, N, Aldecoa, I, de la Iglesia, N, Balana, C. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-18608-8. PMID:36002559. IF:4.600(Q2/4D).

Maroto, P, Porta, C, Capdevila, J, Apolo, AB, Viteri, S, Rodriguez-Antona, C, Martin, L, Castellano, D. Cabozantinib for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221107112. PMID:35847482. IF:4.900(Q2/4D).

Castellano, D, Apolo, AB, Porta, C, Capdevila, J, Viteri, S, Rodriguez-Antona, C, Martin, L, Maroto, P. Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. Therapeutic Advances in Medical Oncology. 2022; 14DOI:10.1177/17588359221108691. PMID:35923927. IF:4.900(Q2/4D).

Chow, LQM, Barlesi, F, Bertino, EM, van den Bent, MJ, Wakelee, HA, Wen, PY, Chiu, CH, Orlov, S, Chiari, R, Majem, M, McKeage, M, Yu, CJ, Garrido, P, Hurtado, FK, Arratia, PC, Song, YB, Branle, F, Shi, M, Kim, DW. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. CLINICAL CANCER RESEARCH. 2022; 28(12)DOI:10.1158/1078-0432.CCR-21-1838. PMID:35091443. IF:11.500(Q1/1D).

Majem, M, Goldman, JW, John, T, Grohe, C, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Li, SQ, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Atagi, S, Zeng, LM, Kulkarni, D, Medic, N, Tsuboi, M, Herbst, RS, Wu, YL. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. CLINICAL CANCER RESEARCH. 2022; 28(11)DOI:10.1158/1078-0432.CCR-21-3530. PMID:35012927. IF:11.500(Q1/1D).

Blay, JY, Palmerini, E, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara-Altamirano, MA, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, Tos, APD, Malagon, HRD, Donati, DM, Dufresne, A, Eriksson, M, Farias-Loza, M, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gerderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Hindi, N, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes, A, David, BBL, Lopez-Pousa, A, Lutter, G, Maki, RG, Martinez-Said, H, Martinez-Tlahuel, JL, Mello, CA, Perez, JMM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Santos, TG, Scotlandi, K, Silva, MLG, Soule, T, Stacchiotti, S, Valverde, CM, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for bone sarcoma. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103685. PMID:35460913. IF:6.200(Q1/3D).

Mulet, M, Osuna-Gomez, R, Zamora, C, Porcel, JM, Nieto, JC, Perea, L, Pajares, V, Munoz-Fernandez, AM, Calvo, N, Sorolla, MA, Vidal, S. Influence of Malignant Pleural Fluid from Lung Adenocarcinoma Patients on Neutrophil Response. Cancers. 2022; 14(10)DOI:10.3390/cancers14102529. PMID:35626131. IF:5.200(Q2/3D).

Adam, R, Tibau, A, Valiente, CM, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. PLoS One. 2022; 17(6)DOI:10.1371/journal.pone.0268545. PMID:35687539. IF:3.700(Q2/4D).

Nadal E., Oré-Arce M., Remon J., Bernabé-Caro R., Covela-Rúa M., de Castro-Carpeño J., Massutí-Sureda B., Guillot-Morales M., Majem M., Maestu-Maiques I., Morilla-Ruíz I., Gironés R.. Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer. Clinical & Translational Oncology. 2023; 25(11)DOI:10.1007/s12094-023-03286-3. PMID:37566345. IF:2.800(Q2/5D).

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, López-Vacas R, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez-Ruiz E, González-Cao M, Oramas J, Magdaleno A, Fra J, Martín-Carnicero A, Corral M, Puértolas T, Ramos-Ruiz R, Dittmann A, Nanni P, Fresno Vara JÁ, Espinosa E. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.. Cancers. 2023; 15(17)DOI:10.3390/cancers15174407. PMID:37686682. IF:4.500(Q1/3D).

Garcia-Saenz, JA, Blancas, I, Echavarria, I, Hinojo, C, Margeli, M, Moreno, F, Pernas, S, Cajal, TRY, Ribelles, N, Bellet, M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03203-8. PMID:37148499. IF:2.800(Q2/5D).

Sanchez-Heras, A, Cajal, TRY, Pineda, M, Aguirre, E, Grana, B, Chirivella, I, Balmana, J, Brunet, J. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03202-9. PMID:37133731. IF:2.800(Q2/5D).

Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, O, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03216-3. PMID:37418123. IF:2.800(Q2/5D).

Garcia-Campelo, R, Sullivan, I, Arriola, E, Insa, A, Vidal, OJ, Cruz-Castellanos, P, Moran, T, Reguart, N, Zugazagoitia, J, Domine, M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (vol 25, pg 2679, 2023). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03290-7. PMID:37556098. IF:2.800(Q2/5D).

Segura, PP, Quintela, NV, Garcia, MM, Berron, SD, Sarrio, RG, Gomez, JG, Castano, AG, Martin, LMN, Rubio, OG, Losada, EP. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03245-y. PMID:37540408. IF:2.800(Q2/5D).

Serrano C., Álvarez R., Carrasco J.A., Marquina G., Martínez-García J., Martínez-Marín V., Sala M.Á., Sebio A., Sevilla I., Martín-Broto J.. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical & Translational Oncology. 2023; 25(9)DOI:10.1007/s12094-023-03177-7. PMID:37129716. IF:2.800(Q2/5D).

Garcia-Carbonero R., González Astorga B., Vidal Tocino R., Contreras Toledo D., Pericay C., Fernández Montes A., Falcó E., González Cordero M., Reina Zoilo J.J., Alonso V., Rodríguez Salas N., Gil-Raga M., Santos C., Páez D., Anton-Pascual B., Aguilar F., Morales P.. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 2023; DOI:10.1007/s12094-023-03309-z. PMID:37651021. IF:2.800(Q2/5D).